clinical trial · NCT06920043
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Metabolic Dysfunction-Associated SteatohepatitisNon-alcoholic Fatty Liver DiseaseEfimosferminPlacebo
brief summary
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
started
Apr 9, 2025
primary completion
Jul 10, 2028
completion
Jul 10, 2028
last updated
Jul 8, 2026
official title
A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol